866-997-4948(US-Canada Toll Free)

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 69 Pages

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural ulcer) Pipeline Review, H1 2017, provides an overview of the Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline landscape.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural ulcer) Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 7, 1, 5 and 1 respectively.

Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer) (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Venous Leg Ulcers (Crural ulcer) - Overview
Venous Leg Ulcers (Crural ulcer) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development
Adocia
CardioVascular BioTherapeutics Inc
CytoTools AG
Factor Therapeutics Ltd
FirstString Research Inc
Mallinckrodt Plc
MediWound Ltd
NovaLead Pharma Pvt Ltd
Promore Pharma
RegeneRx Biopharmaceuticals Inc
RMB-Research GmbH
Venous Leg Ulcers (Crural ulcer) - Drug Profiles
AUP-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CL-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CODA-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CureXcell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EscharEx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LL-37 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLP-328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGN-137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-42909 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Statmicoll - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Venous Leg Ulcers (Crural ulcer) - Dormant Projects
Venous Leg Ulcers (Crural ulcer) - Discontinued Products
Venous Leg Ulcers (Crural ulcer) - Product Development Milestones
Featured News & Press Releases
Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update
Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)
Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US
Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board
May 23, 2016: CytoTools confirms the clinical efficacy of DermaPro in phase II/III trial
Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update
Aug 19, 2015: Macrocure Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell in Venous Leg Ulcers
Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment
Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results
Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications
May 05, 2014: Subsidiary DermaTools Biotech starts European clinical phase II/III trial with wound healing medication DermaPro for ulcus cruris indication
Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by Factor Therapeutics Ltd, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research Inc, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by Mallinckrodt Plc, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by MediWound Ltd, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by Promore Pharma, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
Venous Leg Ulcers (Crural ulcer) - Pipeline by RMB-Research GmbH, H1 2017
Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H1 2017
Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *